Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Testing the Interplay of Gambling, Emotion and Reward

NCT06122298 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2024-03-27
Last updated
2025-07-17

Condition(s) studied

Gambling Addiction

Investigational drug(s) / intervention(s)

fMRIEcological Momentary Assessment

fMRI: A brain imaging technique that measures in vivo the activity of brain areas by detecting local changes in blood flow.

Ecological Momentary Assessment: studies people's thoughts and behaviour in their daily lives by repeatedly collecting data in an individual's normal environment, at or close to the time they carry out that behaviour

Study summary

Background The nature and direction of dysfunctional reward processing in gambling disorder remains unclear. We aim to test a novel neurobiological model of gambling addiction, that takes into account inter-individual differences, as well as the multifactorial nature of gaming addiction.

Objectives

Primary objective:

This project will test the hypothesis that there are two opposite brain phenotypes that characterize two distinct subpopulations of gamblers, so-called impulsive vs. emotional, respectively.

Secondary objective:

This project will also seek to determine whether the brain phenotypes proposed above are capable of predicting gambling behavior outside the laboratory.

Study design The primary objective will be tested using a reward task and a facial emotion recognition task performed by participants in an fMRI scanner.

The secondary objective will be tested by combining fMRI measures with behavioral measures from everyday life collected via Ecological Momentary Assessment (EMA).

Study population This study will focus on individuals with gambling problems, as well healthy subjects with no gambling problems and no psychiatric comorbidities.

Outcomes/Endpoints

Primary endpoint:

We will compare striatum and amygdala reactivity between the three groups of impulsive gamblers, emotional gamblers and healthy subjects.

Secondary endpoint:

We will assess the correlation between emotional states and gambling behavior in everyday life, based on striatum and amygdala reactivity, using multiple linear regression models.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: For all participants (gamblers and healthy subjects) * Aged between 18 and 65 * Fluent French, read and spoken * Male and Female * Informed consent to take part in the research For gamblers : * Number of DSM-5 critera for gambling disorder ≥3 * Score ≥ 5 on the Problem Gambling Severity Index questionnaire (PGSI) * Have a smartphone For healthy subjects : * no DSM-5 criteria for gambling addiction * Score ≤ 2 on the Problem Gambling Severity Index questionnaire (PGSI) Exclusion Criteria: For all participants (gamblers and healthy subjects): * Contra-indication to MRI * Protected Adults * Breast feeding or pregnant women * Neurological disorder or severe chronic illness (diabetes, heart disease, kidney disease, lung disease or liver disease, inflammatory disease….) * Pharmacological treatment with psychotropic action (\>1 time / week) * Regular drug use (\> 1 time/ week for at least 3 months in the last 6 months) * Positive urine drug test on the day of the MRI sessions For gamblers: * Psychiatric treatment \> 1 month (pharmacological or CBT) * Other DSM-5 diagnosis : schizophrenia, bipolar disorder, ADHD, autism, current PTSD, eating disorders, current major depressive episode, anxiety disorder, substance use disorder except nicotine, obsessive compulsive disorder. For healthy subjects : \- Any DSM-5 diagnosis except nicotine addiction

Primary outcome measure(s)

  • Striatal BOLD response to reward outcomes and amygdala BOLD response to emotional stimuli — 4 weeks
    Striatal BOLD response: average BOLD signal as measured with fMRI in the striatum in response to monetary reward outcomes in a gambling task. amygdala BOLD response: average BOLD signal as measured with fMRI in the amygdala in response to emotional faces in a facial emotion recognition task.

Trial sites (1)

FacilityCityRegionStatus
CH le Vinatier Bron France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06122298 on ClinicalTrials.gov ↗ ← All trials in France